Dr. Lal Path Labs Ltd.

15%

s Leading & Trusted Diagnostics Company 70+ years of experience in the field of diagnostics 15% 3 Year Revenue CAGR 13% 3-Year Normalised EBITDA CAGR 120% Equity Dividend for FY 22-23 La

13%

ostics Company 70+ years of experience in the field of diagnostics 15% 3 Year Revenue CAGR 13% 3-Year Normalised EBITDA CAGR 120% Equity Dividend for FY 22-23 Largest* diagnostics chain i

120%

ence in the field of diagnostics 15% 3 Year Revenue CAGR 13% 3-Year Normalised EBITDA CAGR 120% Equity Dividend for FY 22-23 Largest* diagnostics chain in the country with PAN India presenc

rs 24

growth 36 NABL accredited Labs; 2 CAP accredited Labs 111 Mn patients serviced in last 5 years 24% ROCE Excl. Cash & Investments 5191 Pathology & Radiology tests; Comprehensive Test menu 27

Rs. 838

Test menu 277 Labs; Geographically spread-out network 5102 Patient Service Centers (PSC’s) Rs. 838 Cr. Cash & Investments as on 31st March 2023 Rs. 237 Cr. OD/TL as on 31st March 2023 As on Mar

Rs. 237

rk 5102 Patient Service Centers (PSC’s) Rs. 838 Cr. Cash & Investments as on 31st March 2023 Rs. 237 Cr. OD/TL as on 31st March 2023 As on March 31, 2023 *Largest on the basis of revenue and presenc

INR 1954

and 1008 PUP’s of Suburban Diagnostics As on March 31, 2023 5 FY23 – Key Performance Highlights INR 1954 Cr Non-Covid Revenue +16% 70.6 MN Non-Covid Samples +18% 26.6 MN Non-Covid Patients INR 528

16%

stics As on March 31, 2023 5 FY23 – Key Performance Highlights INR 1954 Cr Non-Covid Revenue +16% 70.6 MN Non-Covid Samples +18% 26.6 MN Non-Covid Patients INR 528 Cr Normalised EBITDA* 26%

18%

23 – Key Performance Highlights INR 1954 Cr Non-Covid Revenue +16% 70.6 MN Non-Covid Samples +18% 26.6 MN Non-Covid Patients INR 528 Cr Normalised EBITDA* 26% Margin INR 297 Cr Normalised PA

INR 528

NR 1954 Cr Non-Covid Revenue +16% 70.6 MN Non-Covid Samples +18% 26.6 MN Non-Covid Patients INR 528 Cr Normalised EBITDA* 26% Margin INR 297 Cr Normalised PAT** 15% Margin * Normalised EBITDA ex

26%

16% 70.6 MN Non-Covid Samples +18% 26.6 MN Non-Covid Patients INR 528 Cr Normalised EBITDA* 26% Margin INR 297 Cr Normalised PAT** 15% Margin * Normalised EBITDA excl. RSU, CSR & exceptional

INR 297

Non-Covid Samples +18% 26.6 MN Non-Covid Patients INR 528 Cr Normalised EBITDA* 26% Margin INR 297 Cr Normalised PAT** 15% Margin * Normalised EBITDA excl. RSU, CSR & exceptional expenses **Norma

“in the brands that investments that have made “Our belief is comprehensive creation, network infrastructure scale up, and patient services will be the frontrunners of growth.”

Managing Director said

1

Managing Director said

Commenting on the performance, Mr. Bharath Uppiliappan, Chief Executive Officer said: “Today, Dr Lal PathLabs is in a unique position to both facilitate and reap the advantages of rapid progress in the utilization of diagnostic services. Reliable diagnostic in various stages of tools are now increasingly vital treatment, from health monitoring, disease detection, prognosis, diagnosis, and treatment planning, to post- treatment monitoring. As a result, we are committed to investing in an efficient, technology-enabled network that can handle the growing number of samples. in the brands that investments that have made “Our belief is comprehensive creation, network infrastructure scale up, and patient services will be the frontrunners of growth. Within healthcare, patients are increasingly aligning themselves with trustworthy brands, and therefore, it is crucial that we improve our on-the- ground presence and experience. In order to enhance our performance trajectory, we will continue to e